following a re-submission:
umeclidinium/vilanterol (Anoro®) is accepted for use within NHS Scotland.
Indication under review: As a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease. Two randomised controlled studies demonstrated that after 24 weeks of treatment, umeclidinium/vilanterol significantly improved lung function compared with an inhaled long-acting muscarinic antagonist in patients with moderate to very severe COPD. Indirect comparisons demonstrated comparable efficacy with other combinations of long acting muscarinic antagonist plus long acting beta agonist.
Download detailed advice187KB (PDF)
- Medicine name:
- umeclidinium / vilanterol (Anoro)
- SMC ID:
- As a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease.
- Pharmaceutical company
- GlaxoSmithKline UK Ltd
- BNF chapter
- Respiratory system
- Submission type
- Date advice published
- 09 February 2015